A Phase 1b Study of OrienX010, an Oncolytic Virus, in Unresectable Stage IIIC to IV Melanoma Patients

Authors
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, ZhiHong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, LiLi Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert H. I. Andtbacka, and Jun Guo

Correspondence
Guoj307@126.com

In Brief
- OrienX010 is a modified HSV-1 oncolytic virus for the treatment of melanoma
- Well tolerated
- Local oncolytic effects
- Systemic effects via release of tumor derived antigens (TDAs) and maturation of dendritic cells (mDC) by GM-CSF to activate tumor specific T cells
- Anti-tumor effects in injected and noninjected metastases